First released for Sony E-mount, the Tokina atx-m 11-18mm F2.8 will soon be available for Fujifilm X-mount users.

Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

Standalone canaloplasty and trabeculotomy can deliver meaningfully reduced IOP in the long term and require fewer topical therapy agents.

Patients with varying stages of glaucoma saw no significant difference in outcomes between standard and enhanced monofocal ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Understanding different components of foods and how they affect us has helped many of us clear up misunderstandings and misinformation about important things our body needs to survive like healthy ...

Macular optical coherence tomography imaging should be completed twice a year for most patients with glaucoma to detect progression.

US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials ...

New study challenges conventional wisdom about cholesterol! High levels of 'good cholesterol' may increase the risk of ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...